Abstract: The invention relates to human or humanised, chimeric, monoclonal, class IgG3 antibodies produced in a cell line of rat myeloma, especially line YB2/0. Said antibodies have a strong phagocytosis activity and can be administered for the treatment of cancers and infections.
Type:
Application
Filed:
October 18, 2004
Publication date:
September 20, 2007
Applicant:
Labopratoire Francais du Fractionnement et des Biotechnologies
Inventors:
Christophe Romeuf, Sylvie Jorieux, Dominique Bourel, Philippe Klein, Nicolas Bihoreau